"En 1989, los dos Oncólogos más prestigiosos del Perú, junto con dos reconocidos empresarios, luchaban contra una de las peores enfermedades, pero también contra una dura realidad. Muchas personas estaban desprotegidas dado que contaban con servicios parciales y no con una solución que los ayude a dar una pelea completa. ONCOSALUD nace como respuesta a esa falta de protección. Desde hace más de 25 años nos hemos comprometido con la sociedad en nuestra gran misión de salvar vidas del cáncer a través del fomento de una cultura de prevención y un estilo de vida saludable, así como el desarrollo de programas oncológicos estructurados de manera tal que las personas puedan gozar de la mejor atención, médicos, tecnología y servicios complementarios"

During the past decade, Oncosalud conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oncosalud" #1 collaborator was "Gilead Sciences" with 1 trials as a collaborator and "Pharmacyclics LLC." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Oncosalud" are "Lung Cancer" (1 trials), "Lymphoma, Mantle-Cell" (1 trials), "Non Small Cell Lung Cancer" (1 trials), "Nonsquamous Non Small Cell Lung Cancer" (1 trials) and "Squamous Non Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Oncosalud" in a lesser frequency.

Most popular intervention types in "Oncosalud" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Bortezomib" (1 trials), "Carboplatin" (1 trials), "Domvanalimab" (1 trials), "Ibrutinib" (1 trials) and "Lenalidomide" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oncosalud" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Oncosalud". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Oncosalud, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Oncosalud, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".